2m 2m 2m 2m 2m 2m 2m
C4 THERAPEUTICS (CCCC)
NASDAQ
$4.24+$0.12 (+2.79%)
Price as of Jun 23, 2026 6:57 PM EDT- $455.5MMarket Cap
- 180.27%1-Year Change
- BiotechnologyIndustry
C4 THERAPEUTICS (CCCC)
$4.24+$0.12 (+2.79%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 35.9M +1.02% | 35.6M +71.44% | 20.8M -33.25% | 31.1M -32.08% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 35.9M +1.02% | 35.6M +71.44% | 20.8M -33.25% | 31.1M -32.08% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -104.2M -5.78% | -110.6M -6.01% | -117.7M -0.11% | -117.8M +24.48% | |
Depreciation and Amortization Expense | 2.0M +7.76% | 1.8M -3.30% | 1.9M +12.17% | 1.7M +12.33% | |
Total Operating Expenses | 151.2M -2.60% | 155.2M -2.87% | 159.8M -0.52% | 160.6M +25.57% | |
Operating Profit | -115.2M -3.67% | -119.6M -13.97% | -139.0M +7.33% | -129.5M +57.71% | |
Interest Income | 10.3M -28.28% | 14.4M +47.05% | 9.8M +174.46% | 3.6M +823.77% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 10.3M -28.28% | 14.4M +47.05% | 9.8M +174.46% | 3.6M +823.77% | |
Total Nonoperating Income and Expense | 10.3M -28.28% | 14.4M +84.56% | 7.8M +475.28% | 1.4M +177.30% | |
Income before Taxes | -104.9M -0.30% | -105.2M -19.84% | -131.2M +1.30% | -129.5M +54.41% | |
Income Taxes | 121,000 -7.63% | 131,000 -89.77% | 1.3M N/A | 0 +100.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -105.0M -0.31% | -105.3M -20.51% | -132.5M +3.37% | -128.2M +52.79% | |
Net Income from Continuing Operations Applicable to Common | -104.9M -0.30% | -105.2M -19.84% | -131.2M +2.37% | -128.2M +52.79% | |
Basic EPS and Net Income | -1.27 -16.45% | -1.52 -43.07% | -2.67 +1.91% | -2.62 +43.96% | |
Diluted EPS and Net Income | -1.27 -16.45% | -1.52 -43.07% | -2.67 +1.91% | -2.62 +43.96% | |
Basic Weighted Average Shares | 82.9M +19.49% | 69.4M +39.75% | 49.6M +1.59% | 48.9M +6.12% | |
Diluted Weighted Average Shares | 82.9M +19.49% | 69.4M +39.75% | 49.6M +1.59% | 48.9M +6.12% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 74.6M +34.42% | 55.5M -56.16% | 126.6M +325.46% | 29.8M -60.91% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 74.6M +34.42% | 55.5M -56.16% | 126.6M +325.46% | 29.8M -90.38% | |
Total Current Assets | 258.1M +0.13% | 257.8M -4.95% | 271.2M -5.69% | 287.6M -11.71% | |
Accumulated Depreciation | 10.8M +16.68% | 9.2M +18.97% | 7.8M -4.43% | 8.1M +17.45% | |
Property and Plant and Equipment and Net | 4.7M -18.79% | 5.8M -18.09% | 7.1M -3.62% | 7.4M +138.10% | |
Total Long-Term Assets | 3.7M +38.72% | 2.7M -2.50% | 2.7M +78.44% | 1.5M +180.51% | |
Total Assets | 359.1M +2.71% | 349.6M -7.13% | 376.5M -12.62% | 430.8M -14.98% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 12.5M N/A | 0 -100.00% | 2.3M -81.70% | |
Total Current Liabilities | 33.0M -26.88% | 45.2M +5.64% | 42.8M -4.00% | 44.5M -13.07% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 9.2M -14.61% | |
Total Long-Term Liabilities | 69.5M -21.46% | 88.4M +0.99% | 87.6M -9.78% | 97.1M +47.25% | |
Total Liabilities | 102.5M -23.30% | 133.6M +2.52% | 130.3M -7.96% | 141.6M +20.87% | |
Retained Earnings | -738.7M +16.57% | -633.7M +19.93% | -528.4M +33.47% | -395.9M +47.88% | |
Total Stockholders Equity | 256.6M +18.80% | 216.0M -12.24% | 246.1M -14.91% | 289.2M -25.76% | |
Total Shares Outstanding | 96.9M +37.22% | 70.6M +16.80% | 60.5M +23.49% | 49.0M +0.57% | |
Cash Flow | |||||
Cash from Operating Activities | -98.7M +51.47% | -65.2M -39.01% | -106.8M +0.85% | -105.9M +21.82% | |
Capital Expenditures | 607,000 +237.22% | 180,000 -89.46% | 1.7M -68.92% | 5.5M +330.38% | |
Cash from Investing Activities | -8.6M -83.22% | -51.3M -132.38% | 158.3M +171.04% | 58.4M +130.86% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 126.4M +178.80% | 45.3M -0.34% | 45.5M +3,865.91% | 1.1M -99.33% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -320.53% -4.64% | -336.15% -49.82% | -669.84% +60.80% | -416.56% +132.21% | |
Return on Assets | -29.63% +2.14% | -29.01% -11.62% | -32.82% +20.05% | -27.34% +47.78% | |
Return on Equity | -44.43% -2.52% | -45.58% -7.91% | -49.50% +31.08% | -37.76% +50.89% | |
Revenue Growth | 1.02% -98.57% | 71.44% +314.84% | -33.25% +3.64% | -32.08% -184.59% | |
Current Ratio | 7.81 +36.95% | 5.71 -10.02% | 6.34 -1.77% | 6.46 +1.57% | |
Cash Ratio | 2.26 +83.84% | 1.23 -58.50% | 2.96 +343.20% | 0.67 -55.04% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.00 -100.00% | 0.04 -33.50% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.00 -100.00% | 0.03 -41.83% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow